Mayne Pharma Group said on 17 November 2026 that it had entered into a scheme implementation deed with Gedeon Richter Plc, under which the Budapest-based group will acquire 100% of the Adelaide company for A$6.40 a share in cash. The offer values Mayne's equity at approximately A$604m.
Why Gedeon Richter Plc is buying Mayne Pharma Group Limited
Richter said Mayne's existing portfolio, which includes Richter's estetrol-based combination contraceptive pill, and its US commercial footprint would allow it to bring new treatments to millions of women in the United States. Mayne's chair, Bruce Robinson, said the price recognised the strength of the company's Women's Health and Dermatology/DistributeRx franchises in the US.
Deal terms and financing
The consideration represents a 99.4% premium to Mayne's closing price on 16 November 2026, 124% to the 30-day VWAP and 145% to the 180-day VWAP. Richter will fund the deal from internal cash with no financing condition. The deed includes no-shop and no-talk provisions, a matching right and break and reverse break fees, and the three largest shareholders (Funicular Funds, Bruce Mathieson and Trium Capital, together 22.14%) have said they intend to vote in favour absent a superior proposal.
Regulatory approvals and timing
Conditions include Foreign Investment Review Board approval, US Hart-Scott-Rodino clearance, shareholder and court approval, an independent expert's positive conclusion and completion of the sale of Mayne's International segment to Evaris Pharma, which itself requires ACCC approval. The parties will file a voluntary CFIUS declaration. A scheme meeting is expected in late January 2027 and implementation in mid-to-late March 2027.
Market context
The bid follows Mayne's agreement on 6 November 2026 to sell its International business to Perth-based Evaris Pharma, leaving the company focused solely on the United States. Mayne previously agreed a scheme with Cosette Pharmaceuticals at A$7.40 a share in 2025, a deal that ended in litigation over a material adverse change claim.






